RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

26.87 USD
+0.27 (+1.02%)
Last: Mar 13, 2026, 12:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, RIGL scores 5 out of 10 in our fundamental rating. RIGL was compared to 519 industry peers in the Biotechnology industry. RIGL has an average financial health and profitability rating. RIGL is cheap, but on the other hand it scores bad on growth. With these ratings, RIGL could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • RIGL had positive earnings in the past year.
  • RIGL had a positive operating cash flow in the past year.
  • In the past 5 years RIGL reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • RIGL has a better Return On Assets (46.72%) than 99.23% of its industry peers.
  • The Return On Equity of RIGL (96.34%) is better than 99.42% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.61% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • RIGL has a Profit Margin of 40.17%. This is amongst the best in the industry. RIGL outperforms 97.69% of its industry peers.
  • With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
  • RIGL's Gross Margin of 93.10% is amongst the best of the industry. RIGL outperforms 93.45% of its industry peers.
  • RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. RIGL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
  • There is no outstanding debt for RIGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.76, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
  • RIGL has a Altman-Z score (-1.76) which is comparable to the rest of the industry.
  • RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.88, RIGL belongs to the best of the industry, outperforming 94.80% of the companies in the same industry.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • RIGL has a Debt to Equity ratio of 0.25. This is in the lower half of the industry: RIGL underperforms 65.70% of its industry peers.
  • Although RIGL's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.76
ROIC/WACC6.91
WACC9.18%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a Current ratio of 2.28. This is in the lower half of the industry: RIGL underperforms 73.60% of its industry peers.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a Quick ratio of 2.14. This is in the lower half of the industry: RIGL underperforms 73.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. RIGL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 593.62% over the past year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%

3.2 Future

  • Based on estimates for the next years, RIGL will show a decrease in Earnings Per Share. The EPS will decrease by -2.44% on average per year.
  • RIGL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.25% yearly.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%

3.3 Evolution

RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

8

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.12, which indicates a rather cheap valuation of RIGL.
  • Based on the Price/Earnings ratio, RIGL is valued cheaper than 99.42% of the companies in the same industry.
  • RIGL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.71.
  • With a Price/Forward Earnings ratio of 6.49, the valuation of RIGL can be described as very cheap.
  • RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.46% of the companies in the same industry.
  • RIGL is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 4.12
Fwd PE 6.49
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 99.23% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 98.84% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.16
EV/EBITDA 2.61
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL has a very decent profitability rating, which may justify a higher PE ratio.
  • RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RIGL Dividend Analysis

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/13/2026, 12:01:05 PM)

26.87

+0.27 (+1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap487.69M
Revenue(TTM)N/A
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (78.41%)
Short Float %21.57%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)7.09%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)0.23%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE 4.12
Fwd PE 6.49
P/S 1.73
P/FCF 7.16
P/OCF 7.15
P/B 4.15
P/tB 5.29
EV/EBITDA 2.61
EPS(TTM)6.52
EY24.26%
EPS(NY)4.14
Fwd EY15.41%
FCF(TTM)3.75
FCFY13.97%
OCF(TTM)3.76
OCFY13.98%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number30.83
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.76
F-Score7
WACC9.18%
ROIC/WACC6.91
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 5 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.